In active Crohn disease, risankizumab increased clinical remission and endoscopic response at 12 wk.
Ann Intern Med
; 175(10): JC114, 2022 10.
Article
en En
| MEDLINE
| ID: mdl-36191314
ABSTRACT
SOURCE CITATION D'Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn's disease results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;3992015-30. 35644154.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Enfermedad de Crohn
Límite:
Humans
Idioma:
En
Revista:
Ann Intern Med
Año:
2022
Tipo del documento:
Article